49. A compound of claim 47, wherein Y is pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl.

50. A compound of claim 47, wherein Y is 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.


51. A compound according to any of claims 47-50, wherein R^2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C)alkyl, -OH, -OMe, $-CH_2OH$ and -(1-4C)alkylOH.

52. A compound according to claim 51, wherein R^4 is OH, F, methyl, or CH_2OH.

53. A compound according to claim 52, wherein n is 0, 1 or 2.

54. A compound according to claim 53, wherein R^3 is hydrogen.

55. A compound according to any of claims 1-54, wherein Y has the absolute configuration of Figure **Ia**:



Ia

56. A compound according to any of claims 1-55, wherein R^3 is H.

57. A compound according to any of claims 1-56, wherein n is 0-2 and R^4 is F or Me.

58. A compound according to claim 57, wherein n is 0.

59. A pharmaceutical composition, which comprises a compound of Formula **I** as defined in any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.


60. A method for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula **I** as defined in any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof.

61. The method of claim 60, wherein the disease or disorder is pain.

62. A compound of Formula **I** as defined in any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, for use in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection.

63. A process for the preparation of a compound of claim 1, which comprises:


(a) reacting a corresponding compound of Formula **II**



II

or a reactive derivative thereof with an amine having the formula HNR^1R^2; or


(b) for compounds of Formula **I** where R^1 and R^2 are each hydrogen, reacting a compound of Formula **III**



III

with an inorganic acid; or


(c) for a compound of Formula **I** where R^2 is (alkyl)$NHSO_2$((1-3C alkyl), reacting a compound having the formula **IV**



IV

with (1-3C alkyl)SO_2Cl; or

(d) for compounds of Formula 1 wherein Y is 5-fluoropyridin-2(1H)-one, treating a corresponding compound having the formula **VIII**



VIII

with an acid at elevated temperatures; or

(e) for a compound of Formula **I** wherein R^2 is $CH_2CH(OH)CH_2OH$, treating a corresponding compound having the formula **IX**

49. A compound of claim 47, wherein Y is pyridyl substituted with one or more substituents independently selected from F, methyl and ethyl.

50. A compound of claim 47, wherein Y is 5-fluoropyridin-2(1H)-one optionally substituted with (1-4C)alkyl.


51. A compound according to any of claims 47-50, wherein R^2 is a 3, 4 or 5 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C)alkyl, -OH, -OMe, -CH_2OH and -(1-4C)alkylOH.

52. A compound according to claim 51, wherein R^4 is OH, F, methyl, or CH_2OH.

53. A compound according to claim 52, wherein n is 0, 1 or 2.

54. A compound according to claim 53, wherein R^3 is hydrogen.

55. A compound according to any of claims 1-54, wherein Y has the absolute configuration of Figure **Ia**:



Ia

56. A compound according to any of claims 1-55, wherein R^3 is H.

57. A compound according to any of claims 1-56, wherein n is 0-2 and R^4 is F or Me.

58. A compound according to claim 57, wherein n is 0.

59. A pharmaceutical composition, which comprises a compound of Formula **I** as defined in any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.


60. A compound of Formula I as defined in any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection in a mammal.

61. The compound of claim 60, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is pain.

62. The use of a compound of Formula I as defined in any one of claims 1 to 58, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection.

63. A process for the preparation of a compound of claim 1, which comprises:


(a) reacting a corresponding compound of Formula **II**



II

with an amine having the formula HNR^1R^2; or


(b) for compounds of Formula **I** where R^1 and R^2 are each hydrogen, reacting a compound of Formula **III**



III

with an inorganic acid; or


(c) for a compound of Formula **I** where R^2 is (alkyl)$NHSO_2$((1-3C alkyl), reacting a compound having the formula **IV**



IV

with (1-3C alkyl)SO_2Cl; or

(d) for compounds of Formula I wherein Y is 5-fluoropyridin-2(1H)-one, treating a corresponding compound having the formula **VIII**



VIII

with an acid at elevated temperatures; or

(e) for a compound of Formula **I** wherein R^2 is $CH_2CH(OH)CH_2OH$, treating a corresponding compound having the formula **IX**